乳腺癌HER-2靶向治疗的现状与发展前景

摘要

目的人表皮生长因子受体2（HER2）是表皮生长因子受体（EGFR或ErBb）家族中扮演中心角色的一个成员。本文对HER2靶向治疗的现状与发展方向作一综述。方法查阅Pubmed、中国知网、万方、维普等数据库与乳腺癌HER2靶向治疗方面相关的文章，共纳入52篇文献。结果 HER2信号能够调节细胞增殖、存活和分化，与乳腺癌、胃癌、肺癌与卵巢癌等多种肿瘤的发生发展密切相关。目前使用的HER2靶向治疗有助于改善临床化疗药物疗效、提高患者无疾病生存期和5年存活率，但肿瘤的耐药性也越来越严重，已经引起人们的关注。结论 HER2靶向治疗对提高HER2阳性乳腺癌患者治疗效果起到重要作用，其耐药性需要进一步研究解决。%Objective Human epidermal growth factor receptor 2(HER2)plays a central role in the family of the epidermal growth factor receptor(EGFR or ErhB),this article aims at the present situation and problems of HER2 targeted therapy.Methods The search for relevant articles of HER2 targeted therapy were undertaken in the PubMed, CNKI,Wanfang data and VIP,and total of 52 articles were included.Results HER2 signalling can regulate cell prolif-eration,survival and differentiation,which is closely related to the development of breast cancer,stomach cancer,lung cancer,ovarian cancer and other tumors.HER2 targeted therapies can help to improve the clinical efficacy of chemother-apy drugs and to improve patients disease-free survival and 5-year survival rate,but the drug resistance of cancer be-comes more and more serious,which has been aroused a cause for concern.Conclusion HER2 targeted therapy plays an important role in improving treatment effect of breast cancer.Its drug resistance needs to be further studied,and a more effective treatment is expected to be developed.